Abstract
Both EVL and drug therapy are effective in the prevention of variceal rebleeding. Comparisons between the two modalities are few, and only in cirrhotics. This prospective randomized controlled trial compared EVL with drug therapy (propranolol + ISMN) in the prevention of rebleeds from esophageal varices in cirrhotic and noncirrhotic portal hypertension (NCPH) patients. One hundred thirty-seven variceal bleeders were randomized to EVL (Group I; n = 71) or drug therapy (Group II; n = 66). In Group I, EVL was done every 2 weeks till obliteration of varices. In Group II, propranolol (dose sufficient to reduce heart rate to 55 bpm/maximum tolerated dose) and ISMN (incremental dose up to 20 mg BD) were administered. Group I and II patients had comparable baseline characteristics, follow-up (12.4 vs. 11.1 months), cirrhotics and noncirrhotics [50(70.4%) and 21(29.6%) vs. 51(77.3%) and 15(22.7%)] and frequency of Child’s A (35 vs. 27), B (26 vs. 28), and C (9 vs. 11). The mean daily dose was 109 ± 46 mg propranolol and 34 ± 11 mg ISMN and was comparable in cirrhotic and NCPH patients. Upper GI bleeds occurred in 10 patients in Group I (5 from esophageal varices) and in 18 patients in Group II (15 from esophageal varices) (P = 0.06). The actuarial probability of rebleeding from esophageal varices at 24 months was 22% in Group I and 37% in Group II (P = 0.02). The probability of bleed was significantly higher in Child’s C compared to Child’s A/B cirrhotics (P = 0.02). On subgroup analysis, in NCPH patients, the actuarial probability of bleed at 24 months was significantly lower in Group I compared to Group II (25% vs 37%; P = 0.01). In cirrhotics, there was no difference in the probability of rebleeding between patients in Group I and those in Group II (P = 0.74). In Group II, 25.7% patients had adverse effects of drug therapy and 9% patients had to stop propranolol due to serious adverse effects, none required stopping ISMN. There were 10 deaths, 6 in Group I (bleed related, 1) and 4 in Group II (bleed related, 1); the actuarial probability of survival was comparable (P = 0.39). EVL and combination therapy are equally effective in the prevention of variceal rebleeding in cirrhotic patients. EVL is more effective than drug therapy in the prevention of rebleeds in patients with NCPH and, hence, recommended. However, in view of the small number of NCPH patients, further studies are needed before this can be stated conclusively.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Groupaham DY, Smith JL: The course of patients after variceal hemorrhage. Gastroenterology 80:800–809, 1981
D’Amico G, Pagliaro L, Bosch J: The treatment of portal hypertension: a meta-analytic review. Hepatology 22:332–354, 1995
Stiegmann GV, Goff JS, Michaletz-Onody PA, et al.: Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 326:1527–1532, 1992
Gimson AES, Ramage JK, Panos MZ, Hayllar K, Harrison PM, Williams R, Westaby D: Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding esophageal varices. Lancet 342:391–394, 1993
Laine L, El-Newihi HM, Migikovsky B, Sloane R, Garcia F: Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med 119:1–7, 1993
Sarin SK, Govil A, Jain AK, Guptan RC, Issar SK, Jain M, Murthy NS: Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 26:826–832, 1997
Laine L, Cook D: Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta–analysis. Ann Intern Med 123:280–287, 1995
Lebrec D, Poynard T, Hillon P, Benhamou JP: Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med 305:1371–1374, 1981
Villanueva C, Balanzo J, Novella MT, et al.: Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 334:1624–1629, 1996
Villanueva C, Minana J, Ortiz J, et al.: Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 345:647–655, 2001
Bureau C, Peron JM, Alric L, et al.: “A la carte” treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 36:1361–1366, 2002
Patch D, Sabin CA, Goulis J, Gerunda G, Groupeenslade L, Merkel C, Burroughs AK: A randomized, controlled study of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 123:1013–1019, 2002
Lo GH, Chen WC, Chen MH, Hsu PI, Lin CK, Tsai WL, Lai KH: Band ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal rebleeding. Gastroenterology 123:728–734, 2002
Sarin SK, Sundaram KR, Ahuja RK: Predictors of variceal bleeding: an analysis of clinical, endoscopic and hemodynamic variables, with special reference to intravariceal pressure. Gut 30:1757–1764, 1989
Sarin SK: Noncirrhotic portal fibrosis. Gut 30:406–415, 1989
Sarin SK, Lahoti D, Saxena SP, Murthy S, Makwana UK: Prevalence, classification and natural history of gastric varices: a long–term follow–up study in 568 portal hypertension patients. Hepatology 16:1343–1349, 1992
de Franchis R (ed): Portal Hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. London, Blackwell Science, 2001
Altman DG: Practical Statistics for Medical Research. London, Chapman & Hall, 1991
Kiire CF: Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with noncirrhotic portal fibrosis. BMJ 298:1363–1366, 1989
Toba N, Honjou I, Kadohara M, Hirayama C: Effect of esophageal variceal pressure in a patients with extrahepatic portal obstruction. J Gastroenterol Hepatol Suppl 1:251–253, 1989
Poynard T, Calès P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D: Franco-Italian Multicenter Study Groupoup: beta-adrenergic–antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 324:1532–1538, 1991
Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP: Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 31:1239–1245, 2000
Conn HO: Ammonia tolerance in the diagnosis of esophageal varices: a comparison of the endoscopic, radiologic and biochemical techniques. J Lab Clin Med 70:442–451, 1967
Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS: Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 340:988–993, 1999
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649, 1973
De Franchis R, Primignani M: Why do varices bleed? Gastroenterol Clin North Am 21:85–101, 1992
Burroughs AK, Mezzanotte G, Phillips A, McCormick PA, McIntyre N: Cirrhotics with variceal hemorrhage: the importance of the time interval between admission and the start of analysis for survival and rebleeding rates. Hepatology 9:801–807, 1989
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sarin, S.K., Wadhawan, M., Gupta, R. et al. Evaluation of Endoscopic Variceal Ligation (EVL) Versus Propanolol Plus Isosorbide Mononitrate/Nadolol (ISMN) in the Prevention of Variceal Rebleeding: Comparison of Cirrhotic and Noncirrhotic Patients. Dig Dis Sci 50, 1538–1547 (2005). https://doi.org/10.1007/s10620-005-2877-1
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10620-005-2877-1